Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort

• DOI: 10.1007/s10147-024-02670-5
• Publication Date: 2024-12-18T12:43:17Z
• Authors: Minekatsu Taga; Takeshi Sasaki; Shinichiro Higashi; Shoichi Kimura; Atsuro Sawada; Katsuki Tsuchiyama; Takahiro Inoue; Toshiyuki Kamoto; Naoki Terada
• Keywords: Surgical oncology

This study aimed to evaluate the efficacy of androgen receptor signaling inhibitors (ARSIs) combined with deprivation therapy (ADT) for treating castration-sensitive metastatic prostate cancer in Japanese patients, focusing on effects time development castration-resistant (CRPC) and overall survival (OS). retrospective muti-institutional analysis included 332 patients diagnosed Japan between 2018 2023. The were categorized into two groups: receiving ADT ARSI (ARSI group) those alone or bicalutamide (ADT group). Data demographics, treatments, outcomes compared using Kaplan-Meier method propensity score matching. We found an increasing trend use over time. median CRPC was significantly longer group than (47.1 vs. 15.2 months, p < 0.001); however, no significant differences OS observed before after 1-year-survival rate tended be higher that subgroups high tumor volume (96.1% 85.0%) Gleason grade (98.1% 85.9%). Adding extended but did not affect OS. However, it potentially suppressed short-term risk death high-risk subgroups. highlights need further research explore characteristics whom upfront ARSIs are effective.